Notes
The study was financed by and developed at the request of Stendhal.
Reference
Lasalvia P, et al. Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia. Value in Health Regional Issues : 28 Jan 2020. Available from: URL: https://doi.org/10.1016/j.vhri.2019.08.481
Rights and permissions
About this article
Cite this article
Natalizumab preferred option for relapsing MS in Colombia. PharmacoEcon Outcomes News 847, 20 (2020). https://doi.org/10.1007/s40274-020-6596-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6596-9